TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.

被引：0
|
作者：
Kotani, Daisuke
Kagawa, Yoshinori
Matsubara, Yuki
Bando, Hideaki
Harada, Kazuaki
Takahashi, Naoki
Mihara, Yoshiaki
Nakayama, Izuma
Izawa, Naoki
Kawakami, Takeshi
Masuishi, Toshiki
Hasegawa, Hiroko
Ohta, Takashi
Wakabayashi, Masashi
Yoshino, Takayuki
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[5] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[6] Saitama Canc Ctr, Saitama, Japan
[7] Saiatama Med Univ Int Med Ctr, Hidaka, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] St Marianna Univ Sch Med, Kawasaki, Kanagawa, Japan
[10] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[13] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[14] Natl Canc Ctr Hosp East, Div Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan
[15] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS264
引用
收藏
页码：TPS264 / TPS264
页数：1
相关论文
共 50 条
  • [21] Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Riely, G. J.
    Ahn, M-J.
    Clarke, J.
    Dagogo-Jack, I.
    Felip, E.
    Gelsomino, F.
    Goldman, J. W.
    Hussein, M.
    Johnson, M. L.
    Morgensztern, D.
    Nadal, E.
    Offin, M. D.
    Provencio Pulla, M.
    Ramalingam, S. S.
    Smit, E. F.
    Tsao, A. S.
    Alcasid, A.
    Usari, T.
    Wilner, K.
    Johnson, B.
    ANNALS OF ONCOLOGY, 2024, 35 : 1246 - 1247
  • [22] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer Reply
    Gardner, Caleb
    Kleinman, Arthur
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 880 - 880
  • [23] Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib plus cetuximab ± binimetinib: Subanalysis of BEACON CRC
    Ng, K.
    Ciardiello, F.
    Van Cutsem, E.
    Yaeger, R.
    Yoshino, T.
    Desai, J.
    Wasan, H.
    Alkuzweny, B.
    Zhang, X.
    Tabernero, J.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S372 - S373
  • [24] Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
    Smit, E.
    Ahn, M-J
    Dagogo-Jack, I.
    Felip, E.
    Gelsomino, F.
    Johnson, B.
    Johnson, M.
    Negrao, M. V.
    Offin, M.
    Ramalingam, S.
    Sanborn, R.
    Tsao, A.
    Wilner, K.
    Alcasid, A.
    Usari, T.
    Zhang, X.
    Riely, G.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S77 - S78
  • [25] BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs, choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Kopetz, S.
    Crothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Gollerkeri, F.
    Maharry, K.
    Loupakis, F.
    Hong, Y.
    Steeghs, F.
    Guren, T.
    Arkenau, H.
    Garcia Alfonso, P.
    Sandor, V.
    Christy-Bittel, J.
    Anderson, L.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer
    Huijberts, Sanne C. F. A.
    van Geel, Robin M. J. M.
    Bernards, Rene
    Beijnen, Jos H.
    Steeghs, Neeltje
    FUTURE ONCOLOGY, 2020, 16 (06) : 161 - 174
  • [27] Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T
    Garcia-Alfonso, P.
    Belani, A.
    Zhang, X.
    Tabernero, J.
    ESMO OPEN, 2022, 7 (03)
  • [28] The role of HPSE in BRAF V600E-mutant colorectal cancer.
    Liu, Mengling
    Xu, Xiaojing
    Peng, Ke
    Hou, Pengcong
    Liu, Qing
    Yu, Yiyi
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)
    Kobayashi, S.
    Bando, H.
    Taketomi, A.
    Takamoto, T.
    Shinozaki, E.
    Shiozawa, M.
    Hara, H.
    Yamazaki, K.
    Komori, K.
    Matsuhashi, N.
    Kato, T.
    Kagawa, Y.
    Yokota, M.
    Oki, E.
    Takahashi, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S736 - S737
  • [30] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Gollerkeri, A.
    Maharry, K.
    Christy-Bittel, J.
    Kopetz, S.
    ESMO OPEN, 2021, 6 (06)
12345